✦ LIBER ✦

Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers

✍ Scribed by Michael J. Lamson; John P. Sabo; Thomas R. Macgregor; Joseph W. Pav; Lois Rowland; Amale Hawi; Michael Cappola; Patrick Robinson

Publisher: John Wiley and Sons
Year: 1999
Tongue: English
Weight: 170 KB
Volume: 20
Category: Article
ISSN: 0142-2782
DOI: 10.1002/(sici)1099-081x(199909)20:6<285::aid-bdd187>3.0.co;2-v

No coin nor oath required. For personal study only.

✦ Synopsis

The results of two randomized, single-dose, crossover bioavailability studies are presented which describe the pharmacokinetics and oral bioavailability of nevirapine, a novel nonnucleoside antiretroviral drug. In the first study 12 healthy male volunteers received nevirapine 15 mg via short-term i.v. infusion or orally as a 50 mg tablet or reference solution (50 mg/200 mL). Following the i.v. dose, nevirapine had a low systemic clearance (Mean +/- S.D., Cl = 1.4 +/- 0.3 L/h) and a prolonged elimination phase (t(1/2beta) = 52.8 +/- 14.8 h; MRT = 81.4 +/- 22.4 h). Nevirapine absolute bioavailability was 93 +/- 9% and 91 +/- 8% for the tablet and oral solution, respectively. In the second study, 24 healthy male volunteers were administered nevirapine as a 200 mg production-line tablet or oral reference solution (200 mg/200 mL). There was no significant difference in bioavailability between the tablet and reference solution. Overall, comparison of the pharmacokinetic parameters between the 50 and 200 mg doses indicates that nevirapine is well absorbed at clinically relevant doses. The absorption profiles using deconvolution revealed no evidence of differential enzyme induction between the two doses or routes of administration following a single dose.

📜 SIMILAR VOLUMES

The single dose pharmacokinetics and saf

The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers

✍ Harri Kanerva; Olavi Kilkku; Esa Heinonen; Antti Helminen; Juha Rouru; Simo Tarp 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 2 views

The pharmacokinetics and tolerability of a new putative non-benzodiazepine type anxiolytic compound deramciclane was studied in two consecutive studies. An open dose-escalation design was used to study doses from 0.2 to 50 mg in 18 healthy male volunteers. In the second study doses from 50 to 150 mg

Single dose pharmacokinetics of HEPP, a

Single dose pharmacokinetics of HEPP, a new anticonvulsant in normal healthy volunteers

✍ Dinora F. González-Esquivel; Francisco Rubio-Donnadieu; Guillermo Carvajal S.; H 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

The pharmacokinetics and the dose proportionality of a new anticonvulsant compound, HEPP (D,L-3-hydroxy-3-ethyl-3-phenylpropionamide) was studied in healthy male volunteers as part of the pharmacological evaluation for new drugs. Study was performed administering doses of 250, 375, 500 and 625 mg of

Pharmacokinetics and bioavailability of

Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers

✍ Jamie J. Zhao; J. Douglas Rogers; Sherry D. Holland; Patrick Larson; Raju D. Ami 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 1 views

A study was conducted to (i) characterize the multiple-dose pharmacokinetics of oral montelukast sodium (MK-0476), 10 mg d 71 in healthy young subjects (N 12), (ii) evaluate the pharmacokinetics of montelukast in healthy elderly subjects (N 12), and (iii) compare the pharmacokinetics and oral bioava

Single- and multiple-dose pharmacokineti

Single- and multiple-dose pharmacokinetics of oral dolasetron and its active metabolites in healthy volunteers: part 2

✍ Dan C. Dimmitt; Youn Sung Choo; Lorene A. Martin; Thangam Arumugham; William F. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

The single-and multiple-dose pharmacokinetics and dose-proportionality of oral dolasetron and its active metabolites over the therapeutic dose range was investigated in 18 healthy men. In an open-label, randomized, complete three-way crossover design, each subject received three separate doses: 50,

Dose proportionality and comparison of s

Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16 455) and its enantiomers in healthy male volunteers

✍ Doris K. Robbins; Mark A. Castles; David J. Pack; Vijay O. Bhargava; Scott J. We 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB 👁 1 views

The pharmacokinetics and dose proportionality of fexofenadine, a new non-sedating antihistamine, and its enantiomers were characterized after single and multiple-dose administration of its hydrochloride salt. A total of 24 healthy male volunteers (31 98 years) received oral doses of 20, 60, 120 and

Pharmacokinetics of minoxidil in patient

Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers

✍ Marijke H. Adams; Wesley J. Poynor; William R. Garnett; H. T. Karnes; James J. F 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 1 views

Objectives: To determine the effect of reduced hepatic function on the pharmacokinetics of minoxidil. The pharmacokinetics of antipyrine, lorazepam, and indocyanine green were included as indicators of hepatic function. Methods: Eight mild cirrhotics and eight healthy subjects received antipyrine (p